DEF: LanzaTech Seeks Shareholder Approval for Massive Dilution and Reverse Stock Split Amidst Nasdaq Delisting Threat and Urgent Capital Needs
Proxy Statement
LanzaTech Global, Inc. is calling for a 2025 Annual Meeting of Stockholders to approve critical proposals including a significant increase in authorized shares, a 100-for-1 reverse stock split, and a potential capital raise, all aimed at addressing Nasdaq listing compliance and securing essential funding, which will result in substantial shareholder dilution.
Summary
- LanzaTech Global, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Monday, July 28, 2025, at 2:00 p.m. Central Time.
- Key proposals include the election of two Class II directors, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
- The company is seeking stockholder approval to increase authorized Common Stock from 600,000,000 to 2,580,000,000 shares to facilitate the issuance of shares related to a warrant and a future financing.
- A 100-for-1 reverse stock split is proposed to increase the per-share trading price of Common Stock to meet Nasdaq's $1.00 minimum bid price requirement, following a non-compliance notice received on March 13, 2025.
- Stockholders will vote on amendments to the Certificate of Incorporation to permit action by written consent and to decrease the par value of Common Stock from $0.0001 to $0.0000001 per share.
- Approval is sought for potential 'change of control' and issuance of shares exceeding 19.9% of outstanding Common Stock under Nasdaq Listing Rules 5635(b) and 5635(d), respectively, due to the scale of the proposed transactions.
- The company recently consummated a Preferred Stock Issuance on May 7, 2025, selling 20,000,000 shares of Series A Preferred Stock to LanzaTech Global SPV, LLC (controlled by Khosla Ventures) for $40 million.
- A warrant to purchase 780,000,000 shares of Common Stock at an exercise price of $0.0000001 per share is to be issued to the Purchaser, contingent on stockholder approvals and a subsequent financing.
- LanzaTech is obligated to seek a 'Subsequent Financing' of $35 million to $60 million by selling Common Stock at $0.05 per share (pre-split), which could result in the issuance of 700,000,000 to 1,200,000,000 shares.
- Failure to obtain stockholder approvals for the increased authorized shares and subsequent financing would trigger a Mandatory Redemption event for the Preferred Stock, for which the company cannot assure sufficient liquidity.
- The company reported a Net Loss of $(137.70) million for fiscal year 2024, compared to $(134.10) million in 2023 and $(76.36) million in 2022.
- Audit fees for 2024 were $2,203,592, and total fees for 2023 were $2,478,471.
Sentiment
Score: 2
Explanation: The sentiment is highly negative due to the severe dilution required, the Nasdaq delisting threat, and the explicit statement of potential liquidity issues if the capital raise and associated proposals are not approved. While the company is taking steps to address its challenges, the underlying financial distress and the magnitude of dilution indicate a very difficult situation for existing shareholders.
Positives
- The proposed amendments to the Certificate of Incorporation, including allowing stockholder action by written consent, enhance corporate governance and stockholder rights.
- The company is actively seeking additional capital, which is critical for its long-term success and operations.
- The Board of Directors is committed to maintaining the company's Nasdaq listing, which is beneficial for stock liquidity and investor appeal.
- New directors Reyad Fezzani, Thierry Pilenko, and Jill Frizzley bring extensive experience in renewable energy, technology, and corporate governance to the Board.
Negatives
- The proposed transactions, including the warrant exercise and subsequent financing, could result in significant dilution of existing stockholders' ownership and voting interests, potentially increasing outstanding shares by 853.6% pre-split.
- The company received a Nasdaq notice on March 13, 2025, for failing to meet the $1.00 minimum bid price requirement, indicating a struggling stock performance.
- Failure to obtain stockholder approvals for the increased authorized shares and subsequent financing would trigger a Mandatory Redemption event for the Preferred Stock, and the company cannot assure sufficient liquidity to make this payment.
- The issuance of shares will concentrate ownership, with Khosla Ventures and its affiliates potentially owning approximately 48.7% of outstanding Common Stock post-transaction, which could limit trading activity and influence corporate decisions.
- The company has experienced significant net losses: $(137.70) million in 2024, $(134.10) million in 2023, and $(76.36) million in 2022.
- There is no assurance that the reverse stock split will increase the stock price proportionately or attract new investors, and it may decrease liquidity and increase transaction costs for odd lots.
Risks
- Substantial dilution of existing stockholders' economic and voting interests due to the issuance of new shares upon conversion of Preferred Stock, exercise of the Warrant, and a future Financing.
- Risk of delisting from Nasdaq if the company fails to regain compliance with the $1.00 minimum bid price rule, or if Nasdaq exercises its discretionary authority due to substantial dilution.
- Inability to raise necessary capital if the Requisite Stockholder Approvals are not obtained, which would greatly limit the company's operations.
- Mandatory Redemption event for Preferred Stock if sufficient authorized shares are not obtained for the Warrant exercise and Subsequent Financing, with no assurance of sufficient liquidity to make the payment.
- Concentration of share ownership in a limited number of holders (e.g., Khosla Ventures and affiliates potentially owning ~48.7% post-transaction), which could further limit trading activity and allow significant influence over company matters.
- Uncertainty regarding the effectiveness of the reverse stock split in increasing and sustaining the stock price, potentially leading to decreased liquidity and higher transaction costs.
- The company has not entered into definitive agreements for a Financing, and there is no assurance when or if such agreements will be reached.
Future Outlook
The company is actively seeking additional capital through a 'Subsequent Financing' or 'Other Financing' to support its operations, contingent on obtaining Requisite Stockholder Approvals. The 'Subsequent Financing' is targeted to raise between $35 million and $60 million at a price of $0.05 per share (pre-split) and must be consummated within 45 days of receiving stockholder approvals. The company expects to file the Certificate of Amendment for the Increased Authorized Share Proposal, Par Value Amendment, and Written Consent Amendment promptly after the Annual Meeting, and the Reverse Stock Split Amendment after the Increased Authorized Share Amendment. The Board will determine the exact timing of the Reverse Stock Split based on market conditions and the need to maintain Nasdaq listing.
Management Comments
- "The Annual Meeting is intended to satisfy our obligations under the Purchase Agreement and to provide us with greater flexibility to seek additional financing."
- "Our Board of Directors strongly recommends you vote FOR each of the following proposals."
- "We believe that hosting a virtual Annual Meeting is in the best interest of the Company and its stockholders. We believe a virtual Annual Meeting enables increased stockholder attendance and participation because stockholders can participate from any location around the world while reducing the carbon footprint that would be required for stockholders to travel to and attend an in-person meeting."
- "We are actively seeking additional capital and we have entered into confidentiality agreements with various potential investors, including certain of our existing stockholders."
- "We and our Board believe that it is advisable and in our and our stockholders best interests, and critical to our long-term success, to increase the number of authorized shares of our Common Stock."
- "The Board has determined that it is advisable and in the best interests of the Company and its stockholders to reduce the number of shares of Common Stock outstanding with the primary intent of increasing the per share trading price of the Common Stock in order to meet the listing requirements of the Nasdaq Capital Market."
- "Our Board is committed to strong corporate governance and believes in maintaining policies and practices that serve the best interests of all stockholders."
Industry Context
LanzaTech operates in the capital-intensive renewable energy and biotechnology sector, which often requires significant funding for research, development, and commercialization of new technologies. The need for a substantial capital raise and the challenges in maintaining Nasdaq listing due to a low share price are common issues for companies in this space, especially those in growth stages or facing market headwinds. The proposed financing structure, involving preferred stock, warrants, and a subsequent equity raise, reflects a common strategy for companies seeking to secure funding from strategic investors or existing large shareholders when traditional public market financing might be challenging due to valuation or market conditions. The emphasis on reducing carbon footprint for the annual meeting aligns with broader ESG trends in the industry.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class II Director | Gary Rieschel | 2025-07-28 | Will not seek re-election and will step down at the conclusion of the Annual Meeting. | |
| Class II Director | Reyad Fezzani | 2025-01-01 | Appointment to the Board. | |
| Class I Director | Thierry Pilenko | 2025-01-01 | Appointment to the Board. | |
| Class III Director | Jill Frizzley | 2025-03-01 | Appointment to the Board. | |
| Chief Financial Officer | Sushmita Koyanagi | 2025-06-02 | Promotion from Chief Accounting Officer. | |
| Chief Accounting Officer | Sushmita Koyanagi | Michael Heraty | 2025-06-02 | Promotion from Vice President Internal Audit & SOX Compliance. |
| General Counsel and Corporate Secretary | Joseph Blasko | 2025-06-13 | Resignation from position. | |
| Interim General Counsel | Amanda Koenig Fuisz | 2025-06-13 | Promotion from Deputy General Counsel. | |
| Deputy General Counsel and Corporate Secretary | Ryan Replogle | 2025-06-13 | Promotion from Deputy General Counsel. | |
| President | Aura Cuellar | 2024-03-01 | Promotion from Executive Vice President of Growth and Strategic Projects. | |
| Chief Technology Officer | Robert Conrado, Ph.D. | 2024-03-01 | Promotion from Vice President of Engineering Design and Development. | |
| Chief Innovation Officer | Michael Kpke, Ph.D. | 2023-07-01 | Promotion from Vice President Synthetic Biology. | |
| Chief Science Officer | Zarath Summers, Ph.D. | 2023-07-01 | Appointment to position. | |
| Chief People Officer | Chad Thompson | 2022-10-01 | Appointment to position. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Bylaw Amendment Proposal | Proposal to amend the Certificate of Incorporation to permit stockholders to act by written consent, enhancing stockholder rights. | Upon filing of Certificate of Amendment (if approved) | Increases stockholder influence by allowing actions without a physical meeting, potentially streamlining certain corporate decisions. |
| Board Composition | The Board consists of nine directors, generally divided into three classes with three-year terms. Holders of Preferred Stock are entitled to elect one Series A Director, who is not included in any class. | Ongoing | Maintains a staggered board structure, which can provide stability but may also make hostile takeovers more difficult. The Series A Director provision grants specific governance rights to Preferred Stockholders. |
| Director Independence | A majority of Board members (Barbara Byrne, Reyad Fezzani, Jill Frizzley, Nigel Gormly, Dorri McWhorter, Jim Messina, Thierry Pilenko, Gary Rieschel) are determined to be independent under Nasdaq listing standards. | Ongoing | Ensures strong independent oversight of management and adherence to best practices for public companies. |
| Board Leadership Structure | The CEO (Dr. Jennifer Holmgren) also serves as Chair of the Board, with Jim Messina serving as Lead Independent Director. | Ongoing | Combines leadership roles, which can provide unified vision, but is counterbalanced by a strong Lead Independent Director to ensure independent oversight and stockholder representation. |
| Risk Oversight Delegation | The Board oversees risk management directly and through its standing committees, with primary responsibility for cybersecurity matters delegated to the Audit Committee. | Ongoing | Establishes a structured approach to risk management, integrating it into committee responsibilities and ensuring regular reporting to the full Board. |
| Executive Compensation Recovery Policy | Adopted an executive compensation recovery (clawback) policy compliant with Nasdaq and SEC rules, allowing mandatory recoupment of erroneously-awarded incentive-based compensation. | 2023-08-31 | Enhances accountability for executive officers and aligns compensation with accurate financial reporting, protecting shareholder interests. |
| Insider Trading and Hedging Policies | Maintains an insider trading policy and a policy prohibiting employees and directors from hedging, short-selling, purchasing on margin, or pledging company securities. | Ongoing | Promotes ethical conduct and prevents conflicts of interest, aligning the interests of insiders with long-term shareholder value. |
Related Party Transactions
- On May 7, 2025, LanzaTech entered into a Series A Convertible Senior Preferred Stock Purchase Agreement with LanzaTech Global SPV, LLC, an entity controlled by Khosla Ventures (a beneficial owner of more than 5% of the company's voting securities).
- Pursuant to this agreement, LanzaTech issued and sold 20,000,000 shares of Preferred Stock to the Purchaser for $40 million.
- The company also agreed to issue a warrant to the Purchaser to purchase 780,000,000 shares of Common Stock at a nominal exercise price, contingent on stockholder approvals and a subsequent financing.
- Khosla Ventures, as the Majority Holder of Preferred Stock, has consent rights over any 'Other Financing' and certain other corporate actions, and has agreed to vote its pre-May 7, 2025 Common Stock in favor of the Requisite Stockholder Approvals.
Stakeholder Impact
- **Shareholders**: Will experience significant dilution (estimated 853.6% pre-split) if the capital raise and associated proposals are approved. Their voting power will also be diluted, and ownership will be concentrated in a few large holders. The reverse stock split aims to maintain Nasdaq listing, which could benefit liquidity, but its effectiveness is uncertain. Failure to approve proposals could lead to delisting and a mandatory redemption event for Preferred Stock, potentially impacting the company's ability to make payments.
- **Employees**: The company's ability to raise capital is critical for its continued operations and long-term success, which directly impacts job security and future opportunities. Equity awards held by employees will be proportionately adjusted by the reverse stock split.
- **Creditors**: The company's ability to secure additional financing and avoid a mandatory redemption event for Preferred Stock (which could trigger liquidity issues) is crucial for its financial stability and ability to meet its obligations.
- **Customers/Suppliers**: The successful capital raise and continued operations are essential for the company to deliver on its projects and maintain its supply chain, ensuring business continuity.
Next Steps
- Hold the 2025 Annual Meeting of Stockholders on July 28, 2025, to vote on the proposed resolutions.
- If approved, file the Certificate of Amendment for the Increased Authorized Share Proposal, Par Value Amendment, and Written Consent Amendment promptly following the Annual Meeting.
- If approved, file the Reverse Stock Split Amendment promptly following the conclusion of the Annual Meeting and after filing of the Increased Authorized Share Amendment.
- Continue to seek additional capital through a 'Subsequent Financing' or 'Other Financing' following stockholder approvals.
- Work to regain compliance with Nasdaq's $1.00 minimum bid price rule by September 9, 2025, potentially through the reverse stock split.
- The Board and Audit Committee will continue to oversee IT systems and cybersecurity, with quarterly updates from the CISO.
Key Dates
| Date | Description |
|---|---|
| 2022-01-01 | Start of fiscal year 2022 for financial reporting. |
| 2022-12-31 | End of fiscal year 2022 for financial reporting. |
| 2023-01-01 | Start of fiscal year 2023 for financial reporting. |
| 2023-02-08 | Date of vesting for certain restricted stock units. |
| 2023-02-21 | Date Schedule 13G filed by Guardians of New Zealand Superannuation. |
| 2023-03-06 | Date of first installment time vesting for stock options and restricted stock units granted on May 2, 2023. |
| 2023-05-02 | Grant date for certain stock options, performance share units, and restricted stock units. |
| 2023-07-01 | Effective date for Michael Kpke's promotion to Chief Innovation Officer and Zarath Summers' promotion to Chief Science Officer. |
| 2023-08-31 | Date of adoption of executive compensation recovery policy. |
| 2023-10-01 | Effective date for Chad Thompson's promotion to Chief People Officer. |
| 2023-12-31 | End of fiscal year 2023 for financial reporting. |
| 2024-01-01 | Start of fiscal year 2024 for financial reporting. |
| 2024-01-08 | Date of second installment of Joseph Blasko's signing bonus payment. |
| 2024-01-01 | Date of full vesting for stock options granted on June 26, 2020. |
| 2024-01-01 | Effective date for Reyad Fezzani and Thierry Pilenko's appointment as directors. |
| 2024-02-08 | Vesting date for certain restricted stock units for directors. |
| 2024-03-04 | Date of stock option exercise transaction by Freya Burton. |
| 2024-03-05 | Date of stock option exercise transaction by Freya Burton. |
| 2024-03-06 | Vesting date for certain restricted stock units for executive officers. |
| 2024-03-13 | Date LanzaTech received written notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price rule. |
| 2024-03-01 | Effective date for Aura Cuellar's promotion to President and Robert Conrado's promotion to Chief Technology Officer. |
| 2024-03-01 | Effective date for Jill Frizzley's appointment to the Board. |
| 2024-04-04 | Date of RSU award for non-employee directors. |
| 2024-04-05 | Grant date for certain restricted stock units and stock options. |
| 2024-04-25 | Date Nimesh Patel resigned. |
| 2024-05-13 | Date of last installment of Aura Cuellar's signing bonus payment. |
| 2024-08-01 | Effective date for Nigel Gormly's new role at Centre for Sustainable Finance: Toit Tahua. |
| 2024-12-01 | Effective date for Sushmita Koyanagi's role as Chief Accounting Officer. |
| 2024-12-31 | End of fiscal year 2024 for financial reporting. |
| 2025-05-07 | Date of entry into Series A Convertible Senior Preferred Stock Purchase Agreement and consummation of Preferred Stock Issuance. |
| 2025-05-09 | Date of Schedule 13D/A filing by Khosla Ventures. |
| 2025-06-02 | Date of Amendment No. 1 to the Series A Convertible Senior Preferred Stock Purchase Agreement, extending warrant issuance and financing consummation dates. Also, effective date for Sushmita Koyanagi's promotion to CFO and Michael Heraty's promotion to Chief Accounting Officer. |
| 2025-06-03 | Record Date for the 2025 Annual Meeting of Stockholders. |
| 2025-06-06 | Closing price of Common Stock on Nasdaq Capital Market was $0.29. |
| 2025-06-13 | Effective date for Amanda Koenig Fuisz's promotion to Interim General Counsel and Ryan Replogle's promotion to Deputy General Counsel and Corporate Secretary. Also, Joseph Blasko's resignation date. |
| 2025-06-18 | Approximate date of mailing Notice of Internet Availability of Proxy Materials. |
| 2025-07-25 | Deadline for beneficial owners to email legal proxy to CST for voting at the Annual Meeting (2:00 p.m. Central Time). |
| 2025-07-27 | Deadline for Internet proxy votes (11:59 p.m. Eastern Daylight Time). |
| 2025-07-28 | Date of the 2025 Annual Meeting of Stockholders. |
| 2025-09-09 | First Compliance Date for regaining Nasdaq's $1.00 minimum bid price requirement. |
| 2026-02-18 | Deadline for stockholder proposals to be included in the 2026 Annual Meeting proxy statement under Rule 14a-8 (unless meeting date changes). |
| 2026-03-30 | Earliest date for stockholders to provide notice for proposals/nominations for 2026 Annual Meeting under Bylaws (if meeting date is July 28, 2026). |
| 2026-04-29 | Latest date for stockholders to provide notice for proposals/nominations for 2026 Annual Meeting under Bylaws (if meeting date is July 28, 2026). |
| 2026-05-07 | Termination date for the Warrant if Issuance Time does not occur prior to this date. |
| 2028-02-10 | Deadline for performance share units granted on May 2, 2023, to meet vesting conditions. |
| 2028-07-28 | Term expiration for Class II directors elected at the 2025 Annual Meeting. |
| 2030-06-26 | Expiration date for stock options granted on June 26, 2020. |
| 2033-05-02 | Expiration date for stock options granted on May 2, 2023. |
| 2034-04-05 | Expiration date for stock options granted on April 5, 2024. |
Recommendation
strong sellKeywords
LanzaTech, SEC Filing, Proxy Statement, DEF 14A, Annual Meeting, Stockholder Proposals, Capital Raise, Preferred Stock, Warrant, Subsequent Financing, Reverse Stock Split, Share Dilution, Nasdaq Listing, Delisting Risk, Corporate Governance, Executive Compensation, Biotechnology, Renewable Energy, Carbon Capture, Sustainable Fuels
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.